論文 - 詳細
| RRC ID | 56079 |
|---|---|
| 著者 | Feng R, Morine Y, Ikemoto T, Imura S, Iwahashi S, Saito Y, Shimada M. |
| タイトル | Nab-paclitaxel interrupts cancer-stromal interaction through C-X-C motif chemokine 10-mediated interleukin-6 downregulation in vitro. |
| ジャーナル | Cancer Sci |
| Abstract |
Cancer-associated fibroblasts (CAF), derived from stroma of cancer tissues, interact with cancer cells and play an important role in cancer initiation, growth, and metastasis. Nab-paclitaxel (nab-PTX) is a 130 nm albumin-binding paclitaxel and recommended for many types of cancer chemotherapy. The nab-PTX stromal-disrupting effect during pancreatic cancer treatment has been reported. The aim of the present study was to determine the role of nab-PTX in cancer cells and CAF interaction. Cancer cells (MIA PaCa-2 and Panc-1) were cocultured with CAF or treated with CAF conditioned medium, after which their migration and invasion ability, epithelial-mesenchymal transition (EMT)-related marker expression and C-X-C motif chemokine 10 (CXCL10) expression and secretion were detected. Nab-PTX treatment was carried out during the coculture system or during preparation of CAF conditioned medium. Then cancer cell migration and invasion ability, EMT-related marker expression, CXCL10 expression and secretion, and interleukin-6 (IL-6) expression and secretion by CAF were checked After coculture with CAF, migration and invasion ability of cancer cells increased. CAF also downregulated E-cadherin and upregulated N-cadherin and vimentin expression in cancer cells. During coculture or stimulation with cancer cell-cultured medium, CAF significantly increased IL-6 expression and secretion. However, nab-PTX in the coculture system canceled CAF-induced migration and invasion promotion and EMT-related gene changes. Moreover, nab-PTX increased CXCL10 expression of cancer cells which blocked CAF IL-6 expression and secretion. Nab-PTX treatment could increase CXCL10 expression of cancer cells which blocks CAF cancer cell migration and invasion-promoting effect by inhibiting IL-6 expression. |
| 巻・号 | 109(8) |
| ページ | 2509-2519 |
| 公開日 | 2018-8-1 |
| DOI | 10.1111/cas.13694 |
| PMID | 29902349 |
| PMC | PMC6113502 |
| MeSH | Albumins / pharmacology* Biomarkers, Tumor / metabolism Cadherins / metabolism Cell Line, Tumor Cell Movement / drug effects Cell Proliferation / drug effects Chemokine CXCL10 / metabolism* Coculture Techniques Down-Regulation / drug effects* Epithelial-Mesenchymal Transition / drug effects Fibroblasts / drug effects Fibroblasts / metabolism Humans Interleukin-10 / metabolism Interleukin-6 / metabolism* Neoplasm Invasiveness / pathology Paclitaxel / pharmacology* Pancreatic Neoplasms / drug therapy* Pancreatic Neoplasms / metabolism Up-Regulation / drug effects Vimentin / metabolism |
| IF | 4.751 |
| 引用数 | 5 |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 1 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | MIA Paca2(RCB2094) |